CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges

In patients with certain hematologic malignancies, the use of autologous T cells genetically modified to express chimeric antigen receptors (CARs) has led to unprecedented clinical responses. Although progress in solid tumors has been elusive, recent clinical studies have demonstrated the feasibilit...

Full description

Saved in:
Bibliographic Details
Published inNeuro-oncology (Charlottesville, Va.) Vol. 20; no. 11; pp. 1429 - 1438
Main Authors Bagley, Stephen J, Desai, Arati S, Linette, Gerald P, June, Carl H, O'Rourke, Donald M
Format Journal Article
LanguageEnglish
Published England Oxford University Press 09.10.2018
Subjects
Editor's Choice
Reviews
Online AccessGet full text

Cover

More Information
Summary:In patients with certain hematologic malignancies, the use of autologous T cells genetically modified to express chimeric antigen receptors (CARs) has led to unprecedented clinical responses. Although progress in solid tumors has been elusive, recent clinical studies have demonstrated the feasibility and safety of CAR T-cell therapy for glioblastoma. In addition, despite formidable barriers to T-cell localization and effector function in glioblastoma, signs of efficacy have been observed in select patients. In this review, we begin with a discussion of established obstacles to systemic therapy in glioblastoma and how these may be overcome by CAR T cells. We continue with a summary of previously published CAR T-cell trials in GBM, and end by outlining the key therapeutic challenges associated with the use of CAR T cells in this disease.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:1522-8517
1523-5866
DOI:10.1093/neuonc/noy032